pdufa.bio
HomeDecisions › JNJ 2026-03-18

JNJ FDA decision — Mar 18, 2026

✓ APPROVED

Johnson & Johnson — ICOTYDE (icotrokinra) · Plaque psoriasis.

Run-up into the decision (T-120 → T+5)

PDUFA 3/18/26$248.56$176.6910/1/25
Daily close, T-120 (10/1/25) through T+5. Run-up high $248.56 on 3/2/26, low $176.69 on 10/1/25 (T-120 to T-1). FDA decision 3/18/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-18
OutcomeApproved
Drug / candidateICOTYDE (icotrokinra)
CompanyJohnson & Johnson
120-day run-up (T-120→T-1)+34.8%